<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Clinical, histopathological and immunohistochemical study of keratoacanthoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Clinical, histopathological and immunohistochemical study of keratoacanthoma." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848269/bin/RJME-62-2-445-fig5.jpg"/> </div> <div class="text-side"> <h1>Clinical, histopathological and immunohistochemical study of keratoacanthoma.</h1> <p>(A) KA with pseudoepitheliomatous hyperplasia: moderately positive diffuse p53 immunostaining in 1/2 and here and there in 2/3 of the epidermis; (B) Malignant KA: strongly positive diffuse p53 immunostaining in the acantholytic SCC; (C) KA with pseudoepitheliomatous hyperplasia: weakly positive Bcl-2 immunostaining in the basal keratinocytes, and intensely positive immunostaining in the inflammatory infiltrate of the dermis; (D) KA without pseudoepitheliomatous hyperplasia: weakly positive diffuse Bcl-2 immunostaining in the basal keratinocytes, and intensely positive immunostaining in the inflammatory infiltrate of dermis; (E) KA with area of acantholytic SCC: isolated weakly positive Bcl-2 immunostaining in the tumor cells and strongly positive in the inflammatory infiltrate of dermis and in the intratumoral lymphocytes; (F) KA without pseudoepitheliomatous hyperplasia: positive nuclear Ki-67 immunostaining only in the keratinocytes of the basal layer. LSAB/HRP method: (A, C–F) ×40; (B) ×100. Bcl-2: B-cell lymphoma-2; HRP: Horseradish Peroxidase; KA: Keratoacanthoma; LSAB: Labeled Streptavidin–Biotin; SCC: Squamous cell carcinoma</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35024732/" target="_blank">35024732</a></p><p>Type: Premalignant/Malignant, Category: Keratinocytic</p>
</div> </div></div></body></html>